Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Proteostasis Therapeutics stock

Learn how to easily invest in Proteostasis Therapeutics stock.

Proteostasis Therapeutics Inc is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Proteostasis Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PTI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Proteostasis Therapeutics stock price (NASDAQ: PTI)

Use our graph to track the performance of PTI stocks over time.

Proteostasis Therapeutics shares at a glance

Information last updated 2021-02-21.
52-week range$0.00 - $0.00
50-day moving average $2.64
200-day moving average $1.40
Wall St. target price$5.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.50

Buy Proteostasis Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Proteostasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Proteostasis Therapeutics financials

Gross profit TTM $5 million
Return on assets TTM -31.16%
Return on equity TTM -72.38%
Profit margin 0%
Book value $0.71
Market capitalisation $2.9 million

TTM: trailing 12 months

Proteostasis Therapeutics share dividends

We're not expecting Proteostasis Therapeutics to pay a dividend over the next 12 months.

Have Proteostasis Therapeutics's shares ever split?

Proteostasis Therapeutics's shares were split on a 1:20 basis on 22 December 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Proteostasis Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Proteostasis Therapeutics shares which in turn could have impacted Proteostasis Therapeutics's share price.

Proteostasis Therapeutics share price volatility

Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

PTI.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1167. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Proteostasis Therapeutics overview

Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc.

Proteostasis Therapeutics in the news

There are no recent company news

Frequently asked questions

What percentage of Proteostasis Therapeutics is owned by insiders or institutions?
Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.571% by institutions.
How many people work for Proteostasis Therapeutics?
Latest data suggests 44 work at Proteostasis Therapeutics.
When does the fiscal year end for Proteostasis Therapeutics?
Proteostasis Therapeutics's fiscal year ends in December.
Where is Proteostasis Therapeutics based?
Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135
What is Proteostasis Therapeutics's ISIN number?
Proteostasis Therapeutics's international securities identification number is: US74373B1098
What is Proteostasis Therapeutics's CUSIP number?
Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site